ATE403875T1 - Polypeptid-biomarker zur diagnose von morbus alzheimer - Google Patents

Polypeptid-biomarker zur diagnose von morbus alzheimer

Info

Publication number
ATE403875T1
ATE403875T1 AT03792291T AT03792291T ATE403875T1 AT E403875 T1 ATE403875 T1 AT E403875T1 AT 03792291 T AT03792291 T AT 03792291T AT 03792291 T AT03792291 T AT 03792291T AT E403875 T1 ATE403875 T1 AT E403875T1
Authority
AT
Austria
Prior art keywords
alzheimer
disease
diagnosis
human
patients
Prior art date
Application number
AT03792291T
Other languages
English (en)
Inventor
Oezkan Yalkinoglu
Gerhard Koenig
Denis Hochstrasser
Jean-Charles Sanchez
Odile Carrette
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02018283A external-priority patent/EP1394549A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Application granted granted Critical
Publication of ATE403875T1 publication Critical patent/ATE403875T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT03792291T 2002-08-23 2003-08-11 Polypeptid-biomarker zur diagnose von morbus alzheimer ATE403875T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02018283A EP1394549A1 (de) 2002-08-23 2002-08-23 Biomarker zur Diagnose von Alzheimer Erkrankung
EP02026643 2002-11-29

Publications (1)

Publication Number Publication Date
ATE403875T1 true ATE403875T1 (de) 2008-08-15

Family

ID=31947886

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08002793T ATE475888T1 (de) 2002-08-23 2003-08-11 Biomarker zur diagnose von alzheimer
AT03792291T ATE403875T1 (de) 2002-08-23 2003-08-11 Polypeptid-biomarker zur diagnose von morbus alzheimer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT08002793T ATE475888T1 (de) 2002-08-23 2003-08-11 Biomarker zur diagnose von alzheimer

Country Status (10)

Country Link
EP (3) EP2221620B1 (de)
JP (1) JP4405919B2 (de)
AT (2) ATE475888T1 (de)
AU (3) AU2003251702B2 (de)
CA (6) CA2746000C (de)
DE (2) DE60322719D1 (de)
DK (3) DK1953556T3 (de)
ES (3) ES2311751T3 (de)
PT (1) PT1535076E (de)
WO (1) WO2004019043A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1469312A1 (de) * 2003-04-18 2004-10-20 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnose der Alzheimer Krankheit
WO2005001483A2 (en) * 2003-06-27 2005-01-06 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Methods for diagnisis and differential diagnosis of dementia disorders
EP1694816B1 (de) * 2003-11-07 2013-08-28 Ciphergen Biosystems, Inc. Biomarker für morbus alzheimer
US7749716B2 (en) * 2004-05-18 2010-07-06 Vermilllion, Inc. Methods of detecting a fragment of neurosecretory protein VGF for diagnosing alzheimer's disease
GB0502068D0 (en) * 2005-02-01 2005-03-09 King S College London Screening method
AU2006231597B2 (en) * 2005-04-06 2011-11-17 Mosaiques Diagnostics And Therapeutics Ag Polypeptide marker for diagnosing Alzheimer's disease
EP1907838B1 (de) * 2005-06-16 2011-06-01 Vermillion, Inc. Fragment des neurosekretorischen proteins vgf als biomarker für morbus alzheimer
US8304246B2 (en) * 2006-02-28 2012-11-06 Phenomenome Discoveries, Inc. Methods for the diagnosis of dementia and other neurological disorders
JP5357746B2 (ja) * 2006-03-11 2013-12-04 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 末梢性の動脈疾患のためのバイオマーカーとしてのβ−２ミクログロブリン
GB0616230D0 (en) * 2006-08-16 2006-09-27 Univ Cambridge Tech Biomarkers and uses thereof
WO2008095275A1 (en) 2007-02-08 2008-08-14 Phenomenome Discoveries Inc. Methods for the treatment of senile dementia of the alzheimer's type
EP2279420B1 (de) 2008-03-21 2014-01-29 Manuela G. Neuman VERFAHREN ZUR DIFFERENTIELLEN DIAGNOSE VON MORBUS ALZHEIMER GEGEN FRONTOTEMPORALE DEMENZ MIT FAS-L, TNF-alpha UND ccCK-18 ALS BIOMARKER
EP2344881A4 (de) * 2008-09-26 2012-03-07 Univ Melbourne Biomarker für morbus alzheimer
JP2010271078A (ja) * 2009-05-19 2010-12-02 Mcbi:Kk 認知機能障害疾患を含む精神疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患を含む精神疾患の検出方法
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
WO2017120461A1 (en) 2016-01-08 2017-07-13 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
EA035336B1 (ru) 2013-12-09 2020-05-29 Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити Способ лечения связанного со старением когнитивного расстройства или заболевания
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
GB201322094D0 (en) 2013-12-13 2014-01-29 Electrophoretics Ltd Methods and compositions relating to alzheimers disease
AU2016279804B2 (en) 2015-06-15 2019-03-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
KR102572009B1 (ko) * 2020-10-21 2023-08-29 순천향대학교 산학협력단 시스타틴 c를 포함하는 퇴행성 신경 질환 진단용 바이오마커 조성물 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
WO2000025138A2 (en) * 1998-10-23 2000-05-04 Roger Nitsch Methods of diagnosing or prognosing alzheimer's disease
WO2001063294A2 (en) * 2000-02-24 2001-08-30 Oxford Glycosciences (Uk) Limited Diagnosis of bipolar affective disorder (bad) and unipolar depression
EP1266225A2 (de) * 2000-03-20 2002-12-18 Oxford GlycoSciences (UK) Limited Diagnose und behandlung von brustkrebs
EP1325338A2 (de) * 2000-04-03 2003-07-09 Oxford GlycoSciences (UK) Limited Diagnose und behandlung der alzheimerschen krankheit
DE10291524D2 (de) * 2001-04-06 2004-07-01 Anker Thorsten Verfahren zum Nachweis chronisch-demenzieller Erkrankungen, zugehörige Peptide und Nachweisreagenzien
SG121733A1 (en) * 2001-10-03 2006-05-26 Pfizer Prod Inc Nucleic acid molecules polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease

Also Published As

Publication number Publication date
CA2746000A1 (en) 2004-03-04
ES2311751T3 (es) 2009-02-16
EP1953556B1 (de) 2010-07-28
CA2745569C (en) 2015-07-14
CA2496321A1 (en) 2004-03-04
EP2221620A3 (de) 2010-11-24
CA2746000C (en) 2014-10-21
EP1953556A3 (de) 2008-11-26
AU2003251702A1 (en) 2004-03-11
CA2745731C (en) 2015-05-12
CA2745731A1 (en) 2004-03-04
AU2010212316B2 (en) 2012-05-24
AU2010212317B2 (en) 2013-01-10
PT1535076E (pt) 2008-11-03
AU2010212316A1 (en) 2010-09-09
CA2745998C (en) 2013-11-26
CA2745998A1 (en) 2004-03-04
CA2745724C (en) 2015-06-02
WO2004019043A2 (en) 2004-03-04
WO2004019043A3 (en) 2004-06-24
EP1953556A2 (de) 2008-08-06
JP2005536729A (ja) 2005-12-02
AU2010212317A1 (en) 2010-09-09
CA2496321C (en) 2013-05-21
ES2436318T3 (es) 2013-12-30
DK1535076T3 (da) 2008-11-24
EP2221620B1 (de) 2013-10-02
CA2745724A1 (en) 2004-03-04
ES2347924T3 (es) 2010-11-25
DE60333608D1 (de) 2010-09-09
JP4405919B2 (ja) 2010-01-27
EP1535076B1 (de) 2008-08-06
CA2496321E (en) 2004-03-04
EP2221620A2 (de) 2010-08-25
CA2745569A1 (en) 2004-03-04
DE60322719D1 (de) 2008-09-18
AU2003251702B2 (en) 2010-06-03
ATE475888T1 (de) 2010-08-15
DK2221620T3 (da) 2014-01-06
DK1953556T3 (da) 2010-10-25
EP1535076A2 (de) 2005-06-01

Similar Documents

Publication Publication Date Title
ATE403875T1 (de) Polypeptid-biomarker zur diagnose von morbus alzheimer
WO2004058044A3 (en) Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
DE60016178D1 (de) Verfahren zur diagnose und zur charakterisierung von schlaganfall
EP0391714A3 (de) Verfahren zum Nachweis der Alzheimer-Krankheit: Untersuchung des nicht-neuralen Gewebes
ATE386942T1 (de) Verfahren zur voraussage, zur diagnose und zur vergleichenden diagnose von alzheimer
KR930022086A (ko) 아밀로이드 전구체 단백질의 단백질가수분해에 근거한 알츠하이머병(Alzheimer's disease)의 진단분석
DE60332538D1 (de) Oligosaccharid-biomarker für mucopolysaccharidosen und andere verwandte störungen
ATE438657T1 (de) Charakterisierung von granulozytischer ehrlichia und methoden für ihre verwendung.
ATE166107T1 (de) Dna, die für ein roggen-pollen-allergen kodiert
ATE474227T1 (de) Bestimmung von felinem und caninem probnp
ATE168135T1 (de) Diagnose von retinoblastoma
WO2002072751A3 (en) Polynucleotides encoding a metalloprotease, mp-1
DE60133661D1 (de) Nachweismittel von patologischen veränderungen des proteins app und ihre verwendungen
DE60219645D1 (de) Antikörper gegen metastin und dessen verwendung zur diagnose von schwangerschaft
EP1560025A3 (de) Marker spezifisch für Diabetes
WO2004005487A3 (en) Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, bgs42
JP2006519391A (ja) 自閉症の診断
ATE464567T1 (de) Diagnostische und therapeutische verwendung von f-box-proteinen bei morbus alzheimer und verwandten neurodegenerativen erkrankungen
ATE421693T1 (de) Proteine in der diabetes-proteomanalyse
EP1572931A4 (de) Verfahren und zusammensetzungen zur modulation und zum nachweis von wisp-aktivität
MXPA03005500A (es) Proteina humana novedosa que contiene una repeticion rica en leucina, expresada predominantemente en intestino delgado, hlrrsi1.
WO2007062363A3 (en) Method for diagnosing a person having sjogren's syndrome
DE60326269D1 (de) Verfahren zur detektion von prpsc unter verwendung von gruppe ii aminoglykosid antibiotika
DE60334200D1 (de) Verfahren zur messung von neprilysinaktivität
SE8901566D0 (sv) Nya peptider inkluderande en disulfidbindning

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1535076

Country of ref document: EP

EEIH Change in the person of patent owner